|
|
|
| Research progress on the effect of glucocorticoid receptor signaling pathways in bladder cancer |
| FENG Sheng1,2, CHEN Jijun2, ZHENG Yichun2 |
1. Department of Urology, the First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou 310006, China;
2. Department of Urology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China |
|
|
|
Abstract Glucocorticoid receptor (GR) is identified as a member of nuclear receptor family. To exert its biological action, the ligand bound GR is translocated from the cytoplasm into the nucleus by regulating transcriptional signals of related genes. In clinical practice, the effects of glucocorticoid are often mediated by GR signaling pathways. An increasing number of studies have indicated that GR signaling pathways play an essential role in the proliferation, invasion and prognosis of bladder cancer. Meanwhile, the new-generation selective GR activator improves its anti-tumor effects, and at the same time reduces the adverse reactions of hormones, which probably raises the prospect for the treatment of bladder cancer.
|
|
Received: 20 June 2016
|
|
|
糖皮质激素受体信号通路在膀胱癌治疗中的作用研究进展
糖皮质激素受体（GR）是核受体家族中的一员，结合配体后的受体会从细胞质中转位进入细胞核，通过对相关基因转录信号的调控发挥生物学作用。临床上，使用糖皮质激素产生的治疗效果和不良反应几乎都是通过GR信号通路实现的。越来越多的研究表明，GR信号通路与膀胱癌的增殖、侵袭性和预后密切相关，而新一代GR选择性激动剂在提升糖皮质激素抗肿瘤作用的基础上，大大减少了不良反应，有望成为膀胱癌治疗的新方法。
关键词：
膀胱肿瘤/药物疗法,
受体,
糖皮质激素/治疗应用,
信号传导,
转录,
遗传,
综述
|
|
| [[1]] |
CHALASANI V, CHIN J L, IZAWA J I. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer[J]. Can Urol Assoc J, 2009, 3(6 Suppl 4):S193-S198.
|
|
|
| [[2]] |
SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1):5-29.
|
|
|
| [[3]] |
SUN M, TRINH Q D. Diagnosis and staging of bladder cancer[J]. Hematol Oncol Clin North Am, 2015, 29(2):205-218, vii.
|
|
|
| [[4]] |
LESOVAYA E, YEMELYANOV A, SWART A C, et al. Discovery of compound A-a selective activator of the glucocorticoid receptor with anti-inflammatory and anti-cancer activity[J]. Oncotarget, 2015, 6(31):30730-30744.
|
|
|
| [[5]] |
SIONOV R V, SPOKOINI R, KFIR-ERENFELD S, et al. Chapter 6 Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis[M]//Advances in cancer research (volume 101). New York:Academic Press, 2008:127-248.
|
|
|
| [[6]] |
BASCH E, PRESTRUD A A, HESKETH P J, et al. Antiemetics:American Society of Clinical Oncology clinical practice guideline update[J]. J Clin Oncol, 2011, 29(31):4189-4198.
|
|
|
| [[7]] |
ZHENG Y, IZUMI K, LI Y, et al. Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasone-mediated glucocorticoid receptor signals[J]. Mol Cancer Ther, 2012, 11(12):2621-2632.
|
|
|
| [[8]] |
ISHIGURO H, KAWAHARA T, ZHENG Y, et al. Differential regulation of bladder cancer growth by various glucocorticoids:corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity[J]. Cancer Chemother Pharmacol, 2014, 74(2):249-255.
|
|
|
| [[9]] |
ZHENG Y, ISHIGURO H, IDE H, et al. Compound A inhibits bladder cancer growth predominantly via glucocorticoid receptor transrepression[J]. Mol Endocrinol, 2015, 29(10):1486-1497.
|
|
|
| [[10]] |
NICOLAIDES N C, CHARMANDARI E, CHROUSOS G P, et al. Recent advances in the molecular mechanisms determining tissue sensitivity to glucocorticoids:novel mutations, circadian rhythm and ligand-induced repression of the human glucocorticoid receptor[J]. BMC Endocr Disord, 2014, 14:71.
|
|
|
| [[11]] |
ENCÍO I J, DETERA-WADLEIGH S D. The genomic structure of the human glucocorticoid receptor[J]. J Biol Chem, 1991, 266(11):7182-7188.
|
|
|
| [[12]] |
ZHOU J, CIDLOWSKI J A. The human glucocorticoid receptor:one gene, multiple proteins and diverse responses[J]. Steroids, 2005, 70(5-7):407-417.
|
|
|
| [[13]] |
MCBETH L, GRABNAR M, SELMAN S, et al. Involvement of the androgen and glucocorticoid receptors in bladder cancer[J]. Int J Endocrinol, 2015, 2015:384860.
|
|
|
| [[14]] |
MCBETH L, NWANERI A C, GRABNAR M, et al. Glucocorticoid receptor beta increases migration of human bladder cancer cells[J]. Oncotarget, 2016, 7(19):27313-27324.
|
|
|
| [[15]] |
GIGUÉRE V, HOLLENBERG S M, ROSENFELD M G, et al. Functional domains of the human glucocorticoid receptor[J]. Cell, 1986, 46(5):645-652.
|
|
|
| [[16]] |
DAVIES T H, NING Y M, SÁNCHEZ E R. A new first step in activation of steroid receptors:hormone-induced switching of FKBP51 and FKBP52 immunophilins[J]. J Biol Chem, 2002, 277(7):4597-4600.
|
|
|
| [[17]] |
PRATT W B, GALIGNIANA M D, MORISHIMA Y, et al. Role of molecular chaperones in steroid receptor action[J]. Essays Biochem, 2004, 40:41-58.
|
|
|
| [[18]] |
GRAD I, PICARD D. The glucocorticoid responses are shaped by molecular chaperones[J]. Mol Cell Endocrinol, 2007, 275(1-2):2-12.
|
|
|
| [[19]] |
SMOAK K A, CIDLOWSKI J A. Mechanisms of glucocorticoid receptor signaling during inflammation[J]. Mech Ageing Dev, 2004, 125(10-11):697-706.
|
|
|
| [[20]] |
AUPHAN N, DIDONATO J A, ROSETTE C, et al. Immunosuppression by glucocorticoids:inhibition of NF-kappa B activity through induction of I kappa B synthesis[J]. Science, 1995, 270(5234):286-290.
|
|
|
| [[21]] |
AYROLDI E, RICCARDI C. Glucocorticoid-induced leucine zipper (GILZ):a new important mediator of glucocorticoid action[J]. FASEB J, 2009, 23(11):3649-3658.
|
|
|
| [[22]] |
LESOVAYA E A, YEMELYANOV A Y, KIRSANOV K I, et al. Antitumor effect of non-steroid glucocorticoid receptor ligand CpdA on leukemia cell lines CEM and K562[J]. Biochemistry (Mosc), 2011, 76(11):1242-1252.
|
|
|
| [[23]] |
MCKAY L I, CIDLOWSKI J A. Molecular control of immune/inflammatory responses:interactions between nuclear factor-kappa B and steroid receptor-signaling pathways[J]. Endocr Rev, 1999, 20(4):435-459.
|
|
|
| [[24]] |
NOVAC N, BAUS D, DOSTERT A, et al. Competition between glucocorticoid receptor and NFkappaB for control of the human FasL promoter[J]. FASEB J, 2006, 20(8):1074-1081.
|
|
|
| [[25]] |
DE BOSSCHER K, BECK I M, DEJAGER L, et al. Selective modulation of the glucocorticoid receptor can distinguish between transrepression of NF-κB and AP-1[J]. Cell Mol Life Sci, 2014, 71(1):143-163.
|
|
|
| [[26]] |
JAFFUEL D, ROUMESTAN C, BALAGUER P, et al. Correlation between different gene expression assays designed to measure trans-activation potencies of systemic glucocorticoids[J]. Steroids, 2001, 66(7):597-604.
|
|
|
| [[27]] |
WANG X L, HERZOG B, WALTNER-LAW M, et al. The synergistic effect of dexamethasone and all-trans-retinoic acid on hepatic phosphoenolpyruvate carboxykinase gene expression involves the coactivator p300[J]. J Biol Chem, 2004, 279(33):34191-34200.
|
|
|
| [[28]] |
ABBINANTE-NISSEN J M, SIMPSON L G, LEIKAUF G D. Corticosteroids increase secretory leukocyte protease inhibitor transcript levels in airway epithelial cells[J]. Am J Physiol, 1995, 268(4 Pt 1):L601-L606.
|
|
|
| [[29]] |
EHRCHEN J, STEINMVLLER L, BARCZYK K, et al. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes[J]. Blood, 2007, 109(3):1265-1274.
|
|
|
| [[30]] |
ISHIGURO H, KAWAHARA T, ZHENG Y, et al. Reduced glucocorticoid receptor expression predicts bladder tumor recurrence and progression[J]. Am J Clin Pathol, 2014, 142(2):157-164.
|
|
|
| [[31]] |
NISHIMURA K, NONOMURA N, SATOH E, et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer[J]. J Natl Cancer Inst, 2001, 93(22):1739-1746.
|
|
|
| [[32]] |
SCHLOSSMACHER G, STEVENS A, WHITE A. Glucocorticoid receptor-mediated apoptosis:mechanisms of resistance in cancer cells[J]. J Endocrinol, 2011, 211(1):17-25.
|
|
|
| [[33]] |
AZIZ M H, SHEN H, MAKI C G. Glucocorticoid receptor activation inhibits p53-induced apoptosis of MCF10Amyc cells via induction of protein kinase Cε[J]. J Biol Chem, 2012, 287(35):29825-29836.
|
|
|
| [[34]] |
GASCOYNE D M, KYPTA R M, MD V. Glucocorticoids inhibit apoptosis during fibrosarcoma development by transcriptionally activating Bcl-xL[J]. J Biol Chem, 2003, 278(20):18022-18029.
|
|
|
| [[35]] |
HATFIELD K J, REIKVAM H, BRUSERUD Ø. The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia[J]. Curr Med Chem, 2010, 17(36):4448-4461.
|
|
|
| [[36]] |
HE G, KARIN M. NF-κB and STAT3-key players in liver inflammation and cancer[J]. Cell Res, 2011, 21(1):159-168.
|
|
|
| [[37]] |
LING J, KUMAR R. Crosstalk between NF-κB and glucocorticoid signaling:a potential target of breast cancer therapy[J]. Cancer Lett, 2012, 322(2):119-126.
|
|
|
| [[38]] |
GHOSH S, KARIN M. Missing pieces in the NF-kappaB puzzle[J]. Cell, 2002, 109 Suppl:S81-S96.
|
|
|
| [[39]] |
YEMELYANOV A, CZWORNOG J, GERA L, et al. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells[J]. Cancer Res, 2008, 68(12):4763-4773.
|
|
|
| [[40]] |
LESOVAYA E, YEMELYANOV A, KIRSANOV K, et al. Combination of a selective activator of the glucocorticoid receptor compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies[J]. Cell Cycle, 2013, 12(1):133-144.
|
|
|
| [[41]] |
ZHANG L, INSEL P A. Bcl-2 protects lymphoma cells from apoptosis but not growth arrest promoted by cAMP and dexamethasone[J]. Am J Physiol Cell Physiol, 2001, 281(5):C1642-C1647.
|
|
|
| [[42]] |
MELHEM A, YAMADA S D, FLEMING G F, et al. Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues[J]. Clin Cancer Res, 2009, 15(9):3196-3204.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
